MedTrace Logo

Best African American Response to Asthma Drugs

NCT01967173 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 574

Last updated 2018-11-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find the best asthma treatment to add for Blacks who have asthma that is not well controlled on a low dose of inhaled steroid. This study will also try to find out if Black adults and children differ in how they respond to the medications used in this study.

Conditions

Interventions

DRUG

Flovent Diskus® 100 mcg

Flovent is an ICS

DRUG

Flovent Diskus® 250 mcg

Flovent is an ICS

DRUG

Flovent Diskus® 500 mcg

Flovent is an ICS

DRUG

Advair Diskus® 100/50 mcg

Advair is an ICS/LABA combination

DRUG

Advair Diskus® 250/50 mcg

Advair is an ICS/LABA combination

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Milton S. Hershey Medical Center

    lead OTHER

Principal Investigators

  • William Busse, MD · University of Wisconsin, Madison

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2017-07-01
Completion
2017-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01967173 on ClinicalTrials.gov